DARZALEX® + Velcade® (bortezomib) + melphalan + prednisone
DARZALEX® + VMP significantly improved PFS vs VMP alone (P<0.0001)1
Median PFS in the DARZALEX® + VMP regimen had not been reached vs 18.1 months with VMP alone1
Significant improvement in ORR with DARZALEX® + VMP1
Almost all patients (91%) treated with DARZALEX® + VMP demonstrated a clinical response1
91%overall response ratewith DARZALEX® + VMP
74%overall response ratewith VMP alone (P<0.0001)
Speed of response
In responders, median time to response was 0.79 months (range: 0.4 to 15.5 months) in the DARZALEX® + VMP group and 0.82 months (range: 0.7 to 12.6 months) in the VMP group1,2
- Median time to VGPR or better was 2.2 months (range: 0.7, 19.2)
- Median time to CR or better was 8.3 months (range: 1.9, 21.0)
Depth of response
42.6% of patients achieved CR or better with DARZALEX® + VMP vs 24.4% with VMP alone1
Duration of response
Median duration of response had not yet been reached with DARZALEX® + VMP vs 21.3 months (range: 0.5+, 23.7+) with VMP alone1
Significantly higher MRD negativity rate with DARZALEX® + VMP1*
3.6x higher MRD negativity rate with DARZALEX® + VMP vs VMP alone (P<0.0001)1
- MRD based on threshold of 10-5 using a next-generation sequencing assay1,3*
- In patients with CR or better, the MRD negativity rate was 49.7% (n=74)(95% CI: 41.4, 58.0) in the DARZALEX® + VMP arm vs 25.3% (n=22)(95% CI: 16.6, 35.7) with VMP arm1
MRD=minimal residual disease.
*MRD negativity was defined as undetectable levels of multiple myeloma cells by bone marrow aspirate at any time point after the randomization and before disease progression or start of subsequent therapy and in the trial was assessed by means of next-generation sequencing assay at a sensitivity threshold of 10-5 via bone marrow aspirate, collected at initial trial screening, at the time of confirmation of complete response or stringent complete response, and thereafter at 12, 18, 24, and 30 months.1-3
Daratumumab (DARZALEX®) in combination with bortezomib, melphalan, and prednisone is recommended by the NCCN Guidelines® as a preferred Category 1† therapeutic option for non-transplant candidates‡
†Category 1=based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate.
‡Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. Accessed January 4, 2020. All rights reserved. To view the most recent and complete version of the guideline, go online to www.nccn.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.